26 Oct 2026

Portugal has specified how clinical trial sponsors must continue supplying medicines to participants after their involvement in a trial ends. Ministerial Order No. 465/2026/1, published on 23 October and effective the following day, implements obligations established by the Clinical Trials Law enacted in March 2026.

Under the March law, the sponsor must provide the trial medicine and devices needed for its administration free of charge while the investigator considers treatment indispensable and no alternative of comparable efficacy and safety exists. The October order gives operational detail to this requirement rather than introducing the underlying entitlement for the first time.

Sponsors must ordinarily maintain supply until the medicine has entered distribution and access through the National Health Service is secured. The order specifies circumstances in which that obligation may end or resume in relation to public funding decisions, preserving continuity where routine access has not been achieved.

Post-trial treatment arrangements must be addressed in the trial protocol and coordinated between the sponsor, investigator and trial centre. An individually justified clinical assessment must support continued treatment, with safety monitoring maintained. Exceptional changes that could interrupt treatment must be referred to the national clinical research ethics committee and medicines authority.

Sponsors cannot recover the costs of this free supply through a subsequent public financing agreement. The measure reduces uncertainty at the transition between research participation and routine access, although it does not itself confer general reimbursement for the trial medicine.

Source: Official Journal of the Portuguese Republic
Link: Portaria n.º 465/2026/1, de 23 de outubro (Ministerial Order No. 465/2026/1 of 23 October)
Date: 23 October 2026